Myeloid-Derived Suppressor Cells: Possible Link Between Chronic Obstrucive Pulmonary Disease and Lung Cancer;Células mieloides supresoras: Potencial vínculo entre la enfermedad pulmonar obstructiva crónica y el cáncer de pulmón

Archivos de Bronconeumologia

Volumn 52, Issue 1, 2016, Pages 29-35

  Scrimini, Sergio ^a,b,c   Pons, Jaume ^a,b,c   Sauleda, Jaume ^a,b,c  

^a HEALTH RESEARCH INSTITUTE OF THE BALEARIC ISLANDS IDISBA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Antitumor immunity; Arginase 1; Cancer immunoediting; T cell receptor zeta

Indexed keywords

ARGININE; T CELL RECEPTOR ZETA CHAIN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ARGINASE 1; C REACTIVE PROTEIN; FAS LIGAND; FIBRINOGEN; INTERLEUKIN 6; INTERLEUKIN 8; LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR;

CARCINOGENESIS; CATABOLISM; CELL ACTIVITY; CELL EXPANSION; CHRONIC INFLAMMATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DOWN REGULATION; IMMUNOSURVEILLANCE; LUNG CANCER; LYMPHOCYTE FUNCTION; MYELOID DERIVED SUPPRESSOR CELL; RISK FACTOR; SHORT SURVEY; SUPPRESSOR CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNE SURVEILLANCE; TUMOR IMMUNITY; ANTIGEN PRESENTING CELL; CANCER IMMUNOEDITING; CANCER INHIBITION; CELL ACTIVATION; CELL FUNCTION; COMORBIDITY; ENZYME DEGRADATION; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; LEUKOCYTE; MOLECULAR PATHOLOGY; MYELOID-DERIVED SUPPRESSOR CELL; MYELOPOIESIS; NONHUMAN; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE; TUMOR IMMUNOGENICITY; BONE MARROW CELL; COMPLICATION; IMMUNOLOGY; LUNG TUMOR;

BONE MARROW CELLS; HUMANS; IMMUNOLOGIC SURVEILLANCE; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84961200520     PISSN: 03002896     EISSN: 15792129     Source Type: Journal    
DOI: 10.1016/j.arbr.2015.11.006     Document Type: Short Survey

References (66)

1. WHO. Global action plan for the prevention and control of NCDs 2013-2020 [consultado 15 Feb 2015]. Disponible en: http://www.who.int/nmh/publications/ncd-action-plan/en/.
2. Buist A.S., McBurnie M.A., Vollmer W.M., Gillespie S., Burney P., Mannino D.M., et al. International variation in the prevalence of COPD (the BOLD Study): A population-based prevalence study. Lancet. 2007, 370:741-750.
3. Miravitlles M., Soriano J.B., García-Río F., Muñoz L., Duran-Tauleria E., Sanchez G., et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009, 64:863-868.
4. Lopez A.D., Murray C.C. The global burden of disease, 1990-2020. Nat Med. 1998, 4:1241-1243.
5. WHO. Globocan 2012 [consultado 17 Feb 2015]. Disponible en: . http://globocan.iarc.fr/Default.aspx.
6. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015, 65:5-29.
7. Youlden D.R., Cramb S.M., Baade P.D. The International Epidemiology of Lung Cancer: Geographical distribution and secular trends. J Thorac Oncol. 2008, 3:819-831.
8. Vestbo J., Hurd S.S., Agustí A.G., Jones P.W., Vogelmeier C., Anzueto A., et al. Global Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD executive summary. Am J Respir Crit Care Med. 2013, 187:347-365.
9. Miravitlles M., Soler-Cataluña J.J., Calle M., Molina J., Almagro P., Quintano J.A., et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014, 50(Suppl 1):1-16.
10. Han M.K., Agusti A., Calverley P.M., Celli B.R., Criner G., Curtis J.L., et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am J Respir Crit Care Med. 2010, 182:598-604.
11. Agustí A., Edwards L.D., Rennard S.I., MacNee W., Tal-Singer R., Miller B.E., et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A novel phenotype. PLoS One. 2012, 7:e37483.
12. Agustí A., Faner R. Systemic inflammation and comorbidities in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2012, 4:3-46.
13. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009, 33:1165-1185.
14. Sin D.D., Anthonisen N.R., Soriano J.B., Agusti A.G. Mortality in COPD: Role of comorbidities. Eur Respir J. 2006, 28:1245-1257.
15. Swann J.B., Smyth M.J. Immune surveillance of tumors. J Clin Invest. 2007, 117:1137-1146.
16. Ostrand-Rosenberg S., Sinha P. Myeloid-derived suppressor cells: Linking inflammation and cancer. J Immunol. 2009, 182:4499-4506.
17. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell. 2010, 140:883-899.
18. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009, 9:162-174.
19. Serafini P. Myeloid derived suppressor cells in physiological and pathological conditions: The good, the bad, and the ugly. Immunol Res. 2013, 57:172-184.
20. Scrimini S., Pons J., Agustí A., Soriano J.B., Cosio B.G., Torrecilla J.A., et al. Differential effects of smoking and COPD upon circulating myeloid derived suppressor cells. Respir Med. 2013, 107:1895-1903.
21. Kalathil S.G., Lugade A.A., Pradhan V., Miller A., Parameswaran G.I., Sethi S., et al. T-regulatory cells and programmed death 1+ T cells contribute to effector T-cell dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014, 190:40-50.
22. Brody J.S., Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006, 3:535-537.
23. Congleton J., Muers M.F. The incidence of airflow obstruction in bronchial carcinoma, its relation to breathlessness, and response to bronchodilator therapy. Respir Med. 1995, 89:291-296.
24. Loganathan R.S., Stover D.E., Shi W., Venkatraman E. Prevalence of COPD in women compared to men around the time of diagnosis of primary lung cancer. Chest. 2006, 129:1305-1312.
25. Young R.P., Hopkins R.J., Christmas T., Black P.N., Metcalf P., Gamble G.D. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. EurRespir J. 2009, 34:380-386.
26. Wasswa-Kintu S., Gan W.Q., Man S.F., Pare P.D., Sin D.D. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: A systematic review and meta-analysis. Thorax. 2005, 60:570-575.
27. Kuller L.H., Ockene J., Meilahn E., Svendsen K.H. Relation of forced expiratory volume in one second (FEV1) to lung cancer mortality in the Multiple Risk Factor Intervention Trial (MRFIT). Am J Epidemiol. 1990, 132:265-274.
28. Van den Eeden S.K., Friedman G.D. Forced expiratory volume (1 second) and lung cancer incidence and mortality. Epidemiology. 1992, 3:253-257.
29. Hole D.J., Watt G.C., Davey-Smith G., Hart C.L., Gillis C.R., Hawthorne V.M. Impaired lung function and mortality risk in men and women: Findings from the Renfrew and Paisley prospective population study. BMJ. 1996, 313:711-715.
30. Mannino D.M., Aguayo S.M., Petty T.L., Redd S.C. Low lung function and incident lung cancer in the United States: Data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med. 2003, 163:1475-1480.
31. De Torres J.P., Marín J.M., Casanova C., Cote C., Carrizo S., Cordoba-Lanus E., et al. Lung cancer in patients with chronic obstructive pulmonary disease - incidence and predicting factors. Am J Respir Crit Care Med. 2011, 184:913-919.
32. Skillrud D.M., Offord K.P., Miller R.D. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med. 1986, 105:503-507.
33. Turner M.C., Chen Y., Krewski D., Calle E.E., Thun M.J. Chronic obstructive pulmonary disease is associated with lung cancer mortality in a prospective study of never smokers. Am J Respir Crit Care Med. 2007, 176:285-290.
34. De Torres J.P., Bastarrika G., Wisnivesky J.P., Alcaide A.B., Campo A., Seijo L.M., et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest. 2007, 132:193 2-1938.
35. Wilson D.O., Weissfeld J.L., Balkan A., Schragin J.G., Fuhrman C.R., Fisher S.N., et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008, 178:738-744.
36. Zurawska J.H., Jen R., Lam S., Coxson H.O., Leipsic J., Sin D.D. What to do when a smoker's CT scan is normal: Implications for lung cancer screening. Chest. 2012, 141:1147-1152.
37. Thomsen M., Dahl M., Lange P., Vestbo J., Nordestgaard B.G. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012, 186:982-988.
38. Ehrlich P. Ueber den jetzigen Stand der Karzinomforschung. Ned Tijdschr Geneeskd. 1909, 5:273-290.
39. Old L.J., Boyse E.A. Immunology of experimental tumors. Annu Rev Med. 1964, 15:167-186.
40. Thomas L. Discusión. Cellular and Humoral Aspects of the Hypersensitive States 1959, 529-532. Hoeber-Harper, New York. H. Lawrence (Ed.).
41. Burnet F.M. The concept of immunological surveillance. Prog Exp Tumor Res. 1970, 13:1-27.
42. Burnet F.M. Immunological surveillance in neoplasia. Transplant Rev. 1971, 7:3-25.
43. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science. 2011, 331:1565-1570.
44. Finn O.J. Cancer immunology. N Engl J Med. 2008, 358:2704-2715.
45. Chen D.S., Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013, 39:1-10.
46. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFN gamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001, 410:1107-1111.
47. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol. 2004, 22:329-360.
48. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007, 25:267-296.
49. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012, 12:253-268.
50. Baniyash M. TCR zeta-chain downregulation: Curtailing an excessive inflammatory immune response. Nat Rev Immunol. 2004, 4:675-687.
51. Arora M., Poe S.L., Oriss T.B., Krishnamoorthy N., Yarlagadda M., Wenzel S.E., et al. TLR4/MyD88-induced CD11b+Gr-1 int F4/80+ non-migratory myeloid cells suppress Th2 effector function in the lung. Mucosal Immunol. 2010, 3:578-593.
52. Poe S.L., Arora M., Oriss T.B., Yarlagadda M., Isse K., Khare A., et al. STAT1 regulated lung MDSC like cells produce IL10 and efferocytose apoptotic neutrophils with relevance in resolution of bacterial pneumonia. Mucosal Immunol. 2013, 6:189-199.
53. Ray A., Chakraborty K., Ray P. Immunosuppressive MDSC induced by TLR signaling during infection and in resolution of inflammation. Front Cell Infect Microbiol. 2013, 3:52.
54. Rieber N., Brand A., Hector A., Graepler-Mainka U., Ost M., Schäfer I., et al. Flagellin induces myeloid derived suppressor cells: Implications for Pseudomonas aeruginosa infection in cystic fibrosis lung disease. J Immunol. 2013, 190:1276-1284.
55. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat Rev Cancer. 2013, 13:739-752.
56. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res. 2005, 65:3044-3048.
57. Rodríguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev. 2008, 222:180-191.
58. Raber P., Ochoa A.C., Rodríguez P.C. Metabolism of L-arginine by myeloid-derived suppressor cells in cancer: Mechanisms of T cell suppression and therapeutic perspectives. Immunol Invest. 2012, 41:614-634.
59. Brownlie R.J., Zamoyska R. T cell receptor signalling networks: Branched, diversified and bounded. Nat Rev Immunol. 2013, 13:257-269.
60. Grundy S., Plumb J., Lea S., Kaur M., Ray D., Singh D. Down regulation of T cell receptor expression in COPD pulmonary CD8 cells. PLoS One. 2013, 8:e71629.
61. Schmielau J., Finn O.J. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of t-cell function in advanced cancer patients. Cancer Res. 2001, 61:4756-4760.
62. Bronstein-Sitton N., Cohen-Daniel L., Vaknin I., Ezernitchi A.V., Leshem B., Halabi A., et al. Sustained exposure to bacterial antigen induces interferon-gamma-dependent T cell receptor zeta down-regulation and impaired T cell function. Nat Immunol. 2003, 4:957-964.
63. Ezernitchi A.V., Vaknin I., Cohen-Daniel L., Levy O., Manaster E., Halabi A., et al. TCR zeta down-regulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol. 2006, 177:4763-4772.
64. -/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer. J Cancer Res Clin Oncol. 2010, 136:35-45.
65. Agustí A.G., Noguera A., Sauleda J., Sala E., Pons J., Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003, 21:347-360.
66. Scrimini S, Pons J, Agustí A, Clemente A, Crespí Sallán M, Bauçà JM, et al. Expansion of myeloid derived suppressor cells in chronic obstructive pulmonary disease and lung cancer: potential link between inflammation and cancer. Cancer Immunol Immunother. En prensa 2015. [Epub ahead of print]. doi:10.1007/s00262-015-1737-x.